VRCAHIGH SIGNALFINANCIAL10-K

VRCA underwent a dramatic financial restructuring with substantially improved operating losses, meaningfully reduced total liabilities, and a significant reduction in outstanding shares from 92 million to 17 million.

The company appears to have executed a major recapitalization or reverse stock split, evidenced by the 81% reduction in share count alongside substantial improvement in operating performance. While losses narrowed considerably and total liabilities dropped by 65%, the company remains unprofitable and cash flow negative, requiring continued monitoring of liquidity management.

Comparing 2026-03-11 vs 2025-03-11View on EDGAR →
FINANCIAL ANALYSIS

VRCA demonstrated substantial operational improvement with operating losses narrowing meaningfully and net losses declining significantly year-over-year. The company reduced both SG&A expenses by 40% and R&D spending by 25%, while total liabilities dropped 65% to $22.4M. However, cash and equivalents declined 35% to $30.1M, and the company continues to burn cash operationally, indicating ongoing financial challenges despite the improved trajectory.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+82.4%
$2.2M→$4.0M

Interest expense surged 82.4% — significant debt increase or rising rates materially impacting earnings.

Operating Income
P&L
+81.5%
-$65.9M→-$12.2M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+76.6%
-$76.6M→-$17.9M

Net income grew 76.6% — bottom-line growth signals improving overall business health.

Operating Cash Flow
Cash Flow
+71.1%
-$60.9M→-$17.6M

Operating cash flow surged 71.1% — exceptional cash generation, highest quality earnings signal.

Total Liabilities
Balance Sheet
-65%
$64.0M→$22.4M

Liabilities reduced 65% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-43.3%
$29.0M→$16.4M

Current liabilities reduced — improved short-term financial position and working capital health.

SG&A Expense
P&L
-40.1%
$58.8M→$35.2M

SG&A reduced 40.1% — improved cost efficiency or headcount reduction improving operating margins.

Cash & Equivalents
Balance Sheet
-34.9%
$46.3M→$30.1M

Cash declined 34.9% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

R&D Expense
P&L
-25.2%
$11.8M→$8.9M

R&D spending cut 25.2% — could signal cost discipline or concerning reduction in innovation investment.

Current Assets
Balance Sheet
-16.9%
$51.2M→$42.5M

Current assets declined 16.9% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2026-03-11
PRIOR — 2025-03-11
ADDED
See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
s voting and non-voting common equity held by non-affiliates as of June 30, 2025 (the last business day of the registrant's most recently completed second fiscal quarter) based on the closing sale price of $5.30 as reported on the Nasdaq Global Market on that date was approximately $ 27.3 million.
As of March 2, 2026, the registrant had 17,178,786 shares of common stock, $0.0001 par value per share, outstanding.
"Management s Discussion and Analysis of Financial Condition and Results of Operations," but are also contained elsewhere in this Annual Report.
In some cases, you can identify forward-looking statements by the words "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future.
BUSINESS Overview We are a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers.
This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates.
Our commercial product, YCANTH (VP-102), was approved by the U.S.
We have built a specialized sales organization consisting of approximately 40 field employee sales representatives as of December 31, 2025, in the United States focused on pediatric dermatologists, dermatologists, pediatricians and select other primary care health care providers, or HCPs.
If left untreated, molluscum lesions persist for an average of 13 months, with cases remaining unresolved for up to five years.
REMOVED
See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
s voting and non-voting common equity held by non-affiliates as of June 28, 2024 (the last business day of the registrant's most recently completed second fiscal quarter) based on the closing sale price of $7.29 as reported on the Nasdaq Global Market on that date was approximately $ 190.1 millio n.
As of March 5, 2025, the registrant had 91,779,993 shares of common stock, $0.0001 par value per share, outstanding.
Management s Discussion and Analysis of Financial Condition and Results of Operations, but are also contained elsewhere in this Annual Report.
In some cases, you can identify forward-looking statements by the words may, might, will, could, would, should, expect, intend, plan, objective, anticipate, believe, estimate, predict, project, potential, continue and ongoing, or the negative of these terms, or other comparable terminology intended to identify statements about the future.
However, while we may elect to update these forward-looking statements at some point in the future, we undertake no obligation to publicly update any forward looking statements, whether as a result of new information, future events or otherwise, except as required by law.
B USINESS Overview We are a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention .
Our current product portfolio consists of one approved product with several potential follow-on indications, as well as additional pipeline products.
Our commercial product, YCANTH (VP-102),was approved by the U.S.
We are not currently advancing the development of VP-102 for the treatment of external genital warts or VP-103 for the treatment of plantar warts.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →